Bluebird bio — Corporate Update (December 2023)
17 slides from Bluebird bio's corporate update, Dec 11, 2023
Slide 1: LYFGENIA FDA approval
LYFGENIA™ FDA approval December 8, 2023 NASDAQ: BLUE Exhibit 99.1
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation contain certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including
Slide 3: Welcome and opening remarks
Welcome and opening remarks Andrew Obenshain, chief executive officer Clinical data and label highlights Rich Colvin, MD, PhD, chief medical officer Commercial launch plans Tom Klima, chief commercial and operating officer Closing Andrew Obenshain, chief executive officer Q&A
Slide 4: LYFGENIA: Now FDA Approved
LYFGENIA: Now FDA Approved lyFgenia” ((ovotibeglogene autotemcel) suspension for IV infusion
Slide 5: LYFGENIA Clinical Data & Label Highlights
LYFGENIA Clinical Data & Label Highlights Rich Colvin, MD, PhD, Chief Medical Officer
Slide 6: Burden of sickle cell disease
of adults with SCD have end organ damage, with 24% experiencing damage in multiple organs1 1 in 4 in direct medical costs, despite a median age of death of only 45 years old3 of individuals with SCD report giving up a job due to the disease4 1. Chaturvedi S, et al. Am J Hematol. 2018 3; 2. Kato GJ,
Slide 7: LYFGENIA is a custom-designed gene therapy that is uniquely traceable
LYFGENIA is a custom-designed gene therapy that is uniquely traceable A single mutation in the beta-globin gene leads to the production of sickled hemoglobin (HbS) rather than adult hemoglobin (HbA) LYFGENIA is manufactured by transducing autologous CD34+ cells with BB305 LVV βA-T87Q –globin pairs w
Slide 8: LYFGENIA supported by the most robust and longest follow-up of any gene therapy program for SCD
LYFGENIA supported by the most robust and longest follow-up of any gene therapy program for SCD Data as of Feb 13, 2023 *54 patients initiated cell collection in HGB-206 Group A, Group B and Group C. a sVOE is defined as a VOE requiring a hospitalization or multiple visits to an emergency department
Slide 9: Commercial Launch Plans
Commercial Launch Plans Tom Klima, Chief Commercial and Operating Officer
Slide 10: Synergistic network of ZYNTEGLO QTCs preparing to treat SCD patients
Synergistic network of 35 ZYNTEGLO QTCs preparing to treat SCD patients anticipated in early 2024 27 QTCs are ready to receive SCD patient referrals now Activated ZYNTEGLO QTC* Shading indicates target SCD market Anticipate additional QTC network expansion in 2024 100% of ZYNTEGLO QTCs have initiate
Slide 11: Access and reimbursement strategy designed to enable timely, equitable access
Access and reimbursement strategy designed to enable timely, equitable access Advanced discussions with largest commercial payers >15 Medicaid agencies representing ~80% of individuals with SCD in the US are in discussions2 Active engagement with CMMI on innovative payment demonstration (anticipated
Slide 12: Large patient population with projected demand for gene therapy
Large patient population with projected demand for gene therapy 1. 70% figure supported by seven years of internal and external market research; 2. Potential addressable population of 20,000; 3. Data on file; 4. Komodo claims data >20K individuals with sickle cell disease in the U.S. may be addresse
Slide 13: A potential multi billion-dollar opportunity with 20,000 addressable patients in the U.S.
2 A potential multi billion-dollar opportunity with 20,000 addressable patients in the U.S. Strong commercial strategy and projected patient and physician demand Experienced commercial gene therapy team well-positioned to launch LYFGENIA™ 18-month commercial head start leveraging significant ZYNTEGL
Slide 14: ZYNTEGLO and LYFGENIA manufacturing process
ZYNTEGLO® manufacturing process Delivering a consistent manufacturing process is essential for patients, families and providers STAGE 2◇ 70-90 days Bulk of time spent on release testing to deliver high quality drug product Apheresis & Cell Collection Drug Product Manufacturing & Testing Drug Product
Slide 15: Established gene therapy leader poised to unlock shareholder value
Established gene therapy leader poised to unlock shareholder value Established Clinical Leadership 10+ years of gene therapy research 180+ patients treated 8 clinical trials Experienced team 100% focused on successfully commercializing gene therapy in the US Demonstrated Regulatory Success Establish
Slide 16: Thank you to the SCD community
to the SCD warriors, caregivers, advocates, healthcare providers, investigators, HCPs, and our bluebird team who made this milestone possible.
Slide 17: Rich Colvin, MD, PhD chief medical officer Andrew Obenshain chief executive officer Tom Klima
Rich Colvin, MD, PhD chief medical officer Andrew Obenshain chief executive officer Tom Klima chief commercial and operating officer